[18F] K10-008 and preparation method thereof

Abstract

The invention provides [18F] K10-008 and a preparation method thereof. The preparation method comprises the following steps: synthesizing a precursor compound of [18F] K10-008; (2) putting a mixed solution of K2.2. 2 containing < 18 > F <-> ions and potassium carbonate and a precursor compound dissolved in a fluorinated solvent into a reaction container, carrying out a first heating reaction to obtain a reaction solution, adding an acidic material into the reaction solution, and carrying out a second heating reaction to synthesize [< 18 > F] K10-008; 3, the synthesized [18F] K10-008 is purified through a solid-phase extraction column, and a finished product is obtained.According to the [18F] K10-008 and the preparation method thereof, the preparation method can be operated in the PET center and is safe, efficient and high in yield and purity, the yield reaches 8.5% or above, and the purity reaches 98% or above.

Description

Technical Field

[0001] The present invention relates to the technical field of drug synthesis, in particular to a [ 18 F] K10-008 and its preparation method. Background Art

[0002] Cerebral amyloid angiopathy (CAA) is a common cause of stroke and dementia in the elderly. Its pathological characteristic is the deposition of β-amyloid (Aβ) plaques in the walls of cerebral blood vessels. It is associated with serious clinical consequences such as spontaneous cerebral hemorrhage, stroke, and cognitive impairment, making it a key component of the field of cerebrovascular disease and dementia. Imaging techniques, particularly positron emission tomography (PET), have become an important tool for visualizing Aβ plaque deposition.

[0003] To increase the availability of PET tracers in routine clinical practice, several 18 FAβ plaque deposition imaging agents, including [ 18 F]AV-45 Raposo N, Planton M, Péran P, et al. Florbetapir imaging in cerebral amyloid angiopathy-related hemorrhages. Neurology. 2017;89(7):697- 704 )、[ 18 F]AV-1( O’Keefe G, Saunder T, Ng S, et al. Radiation Dosimetry of {beta}-Amyloid Tracers 11 C-PiB and 18 F-BAY94−9172. J. Nucl. Med. 2009, 50, 309 −315 ),[ 18 F]FPIB( Koole M, Lewis D, Buckley C, et al. Whole-body biodistribution and radiation dosimetry of 18 F-GE067: a radioligand for in vivo brain amyloid imaging. J. Nucl. Med. 2009, 50, 818−822 )and[ 18 F]AZD4694 ( Jureus A, Swahn B, Sandell J, et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J. Neurochem. 2010, 114, 784−794 ) have been shown to be effective PET tracers for Aβ plaque deposition in the brain. 11 C]PiB( McCarter SJ, Lesnick TG, Lowe V, et al. Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-βPET Signal. Neurology. 2021;97(18):e1799-e1808 )and[ 18F]AV-45 performs well in identifying Aβ plaque deposits in the brain parenchyma and vascular system. Related studies have shown that it has a high binding rate in patients with suspected cerebral amyloid angiopathy-related cerebral hemorrhage. However, it lacks specific selectivity and will indiscriminately bind to plaques in blood vessels and parenchymal tissues, making it difficult to distinguish Aβ plaque deposits associated with cerebral amyloid angiopathy from Alzheimer's disease. To differentially diagnose Aβ plaque deposits associated with CAA, it is still necessary to specifically detect Aβ plaque deposits on the cerebral vascular wall. 18 F] labeled imaging agent.

[0004] To solve the above problems, studies have reported the use of PET imaging for cerebral amyloid angiopathy [ 68 Ga]P14-032( Zhang Q, Zhao X, Lei P, et al. Evaluating [ 68 Ga]Ga-p14-032 as a Novel PET Tracer for Diagnosis Cerebral Amyloid Angiopathy. Front Neurol. 2021;12: 702185 )and[ 18 F]K10-008( Zha Z, Choi SR, Ploessl K, et al. Multidentate 18F- polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy. J Med Chem. 2011;54(23):8085-98 ) are the research and development results of the two drugs. Both are based on a polydentate styrene pyridine skeleton, which can enhance the binding affinity with Aβ plaque deposits. The high molecular weight limits its ability to cross the blood-brain barrier. It can selectively bind to vascular Aβ and reduce binding to brain parenchymal deposits, which is conducive to accurate CAA diagnosis PET imaging. Summary of the Invention

[0005] The technical problem to be solved by the present invention is to provide a [ 18 F] K10-008 automated synthesis method. The technical solution is as follows:

[0006] The present invention provides a [ 18 F] A method for preparing K10-008, the method comprising:

[0007] 1) Synthesis 18 F] precursor compound of K10-008;

[0008] 2) will contain 18 F - A mixed solution of K2.2.2 ions and potassium carbonate and a precursor compound dissolved in a fluorinated solvent are placed in a reaction vessel for a first heating reaction to obtain a reaction solution, and an acidic substance is added to the reaction solution for a second heating reaction to synthesize [ 18 F]K10-008;

[0009] 3) The synthesized [ 18 F]K10-008 is purified by solid phase extraction column to obtain the finished product.

[0010] Optionally, the temperature of the first heating reaction is 110-130° C., and the reaction time is 10-15 min; the temperature of the second heating reaction is 80-100° C., and the reaction time is 7-10 min.

[0011] Optionally, the fluorinated solvent includes one or more of dimethyl sulfoxide, acetonitrile or N,N-dimethylformamide; and the acidic substance includes one or more of hydrochloric acid, sulfuric acid or phosphoric acid.

[0012] Optionally, in step 2), before the reaction, the radioactive 18 F - The ions were adsorbed by QMA solid phase extraction column and eluted with a mixed solution of K2.2.2 and potassium carbonate to obtain 18 F - A mixed solution of ionic K2.2.2 and potassium carbonate.

[0013] Optionally, in step 3), the synthesized [ 18 After the step of purifying K10-008 by solid phase extraction column, the step further includes: separating and purifying the purified crude product by HPLC; 18 F - ions, and eluted with an organic solvent; wherein, before HPLC separation and purification, ascorbic acid is added to the crude product; after HPLC separation and purification, ascorbic acid is added to the HPLC mobile phase.

[0014] Optionally, the preparation process is carried out on an AllinOne module; the AllinOne module comprises: a K2.2.2 / K2CO3 container connected in sequence through pipelines, 18 F - An ion injector, a precursor compound container, a reaction container and a product collector; the AllinOne module also includes: an acid container, an alkaline container and a first solid-phase extraction column; the acid container and the alkaline container are respectively connected to the reaction container through pipelines; the first solid-phase extraction column is respectively connected to the reaction container and the product collector through pipelines; the reaction container is provided with a heating element.

[0015] Optionally, the AllinOne module further comprises: a QMA solid phase extraction cartridge, a second solid phase extraction cartridge, an HPLC purification device, an HPLC mobile phase container, an organic liquid container, and a waste liquid bottle;

[0016] The 18F-ion injector and the K2.2.2 / K2CO3 container are respectively connected to the liquid inlet of the QMA solid phase extraction column through pipelines; the liquid inlet of the reaction container and the liquid inlet of the waste liquid bottle are respectively connected to the liquid outlet of the QMA solid phase extraction column through pipelines;

[0017] The liquid outlet of the reaction container and the liquid outlet of the organic liquid container are respectively connected to the liquid inlet of the first solid phase extraction column through pipelines, and the liquid inlet of the HPLC purification device and the liquid inlet of the waste liquid bottle are respectively connected to the liquid outlet of the first solid phase extraction column through pipelines;

[0018] The liquid outlet of the HPLC mobile phase container and the liquid outlet of the organic liquid container are respectively connected to the liquid inlet of the second solid phase extraction column through pipelines, and the product collector and the waste liquid bottle are respectively connected to the liquid outlet of the second solid phase extraction column through pipelines.

[0019] Optionally, a three-way valve is provided on each of the pipelines, and the three-way valve is connected to the solenoid valve; a sterile filter membrane is provided on the pipeline connecting the liquid inlet of the product collector and the liquid outlet of the second solid phase extraction column.

[0020] Optionally, the preparation method comprises:

[0021] Radioactive substances produced by accelerators 18 F - Ions are transferred through the shielding gas 18 F - The solution was injected into the ion injector and then injected into the QMA solid phase extraction cartridge. The solution was eluted with a mixed solution of K2.2.2 and potassium carbonate in the K2.2.2 / K2CO3 container. The eluate entered the reaction vessel. Acetonitrile was added to the reaction vessel to azeotropically remove water.

[0022] The precursor compound and the fluorinated solvent are mixed in a precursor compound container and introduced into a reaction container; the temperature in the reaction container is adjusted to 110°C to 130°C by a heating element, and the reaction is carried out for 10 minutes to 15 minutes;

[0023] An acidic substance is added to the reaction vessel through an acid solution container, and the temperature in the reaction vessel is adjusted to 80° C. to 100° C. After a deprotection reaction is carried out for 7 min to 10 min, the temperature is adjusted to freezing point, and after cooling in an ice bath, an alkaline substance is added to the reaction vessel through an alkaline solution container to neutralize and terminate the hydrolysis reaction, thereby obtaining a reaction mixture;

[0024] The reaction mixture is extracted through a first solid phase extraction column to intercept radioactive 18 F - The ionic reactant is extracted by eluting the first solid phase extraction column with an organic solvent in an organic liquid container to obtain a crude product;

[0025] The crude product was passed into HPLC purification device for separation and purification to obtain 18 F - HPLC mobile phase of ionic compounds; extracting the HPLC mobile phase through a second solid phase extraction column to intercept 18 F - Ionic compounds, the second solid phase extractant is eluted with an organic solvent, and the eluate is passed through a sterile filter membrane and collected into a product collector to obtain the final product [ 18 F]K10-008.

[0026] The present invention also provides a [ 18 F] K10-008 was prepared using the above-mentioned preparation method.

[0027] The beneficial effects brought about by the technical solution provided by the embodiment of the present invention include at least:

[0028] An embodiment of the present invention provides a 18 F] K10-008 and its preparation method, which can be performed in a PET center, is safe, efficient, high-yield, and high-purity. Its radiochemical yield is 4.95% to 8.51%, and its purity exceeds 98%. The preparation process can be automated on the AllinOne module, making it easy to achieve large-scale mass production. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0030] Figure 1 This is an embodiment of the present invention. 18 F] Schematic diagram of the preparation device of K10-008;

[0031] Figure 2 yes[ 18 F] Radioactive high performance liquid chromatography (HPLC) profile of K10-008;

[0032] Figure 3 yes[ 18 F]K10-008 and cold compound 19 F] Ultraviolet HPLC (UV) chromatography of K10-008 co-injection.

[0033] Reference numerals:

[0034] 1-K2.2.2 / K2CO3 container; 2- 18 F-ion injector; 3-precursor compound container; 4-reaction container; 5-product collector; 6-acid container; 7-alkali container; 8-HPLC purification device; 9-HPLC mobile phase container; 10-first ascorbic acid container; 11-second ascorbic acid container; 12-QMA solid phase extraction cartridge; 13-first solid phase extraction column; 14-second solid phase extraction column; 15-organic liquid container; 16-waste bottle; 17-acetonitrile container; 18-sterile water reagent bag; 19-mixed liquid syringe; 20-sterile filter membrane; 21-vent filter membrane; 22-three-way valve; 23-solenoid valve. DETAILED DESCRIPTION

[0035] The following examples are used to illustrate the present invention but are not intended to limit the scope of the present invention.

[0036] Example 1

[0037] Figure 1 This is a schematic diagram of the structure of an AllinOne module according to an embodiment of the present invention. Figure 1 As shown, an AllinOne module provided by an embodiment of the present invention comprises: a K2.2.2 / K2CO3 container 1, 18 F ion injector 2, precursor compound container 3, reaction container 4 and product collector 5; the AllinOne module also includes: an acid container 6, an alkaline container 7 and a first solid phase extraction column 13; the acid container 6 and the alkaline container 7 are respectively connected to the reaction container 4 through pipelines; the first solid phase extraction column 13 is respectively connected to the reaction container 4 and the product collector 5 through pipelines; a heating element is provided on the reaction container 4.

[0038] Furthermore, the AllinOne module may also include: a QMA solid phase extraction cartridge 12 , a second solid phase extraction cartridge 14 , an HPLC purification device 8 , an HPLC mobile phase container 9 , an organic liquid container 15 , a waste liquid bottle 16 , a three-way valve 22 and a solenoid valve 23 .

[0039] 18The F ion injector 2 and the K2.2.2 / K2CO3 container 1 are connected to the liquid inlet of the QMA solid phase extraction column 12 through pipelines; the liquid inlet of the reaction container 4 and the liquid inlet of the waste liquid bottle 16 are connected to the liquid outlet of the QMA solid phase extraction column 12 through pipelines; the liquid outlet of the reaction container 4 and the liquid outlet of the organic liquid container 15 are connected to the liquid inlet of the first solid phase extraction column 13 through pipelines, and the liquid inlet of the HPLC purification device 8 and the liquid inlet of the waste liquid bottle 16 are connected to the liquid outlet of the first solid phase extraction column 13 through pipelines. The liquid outlet of the HPLC mobile phase container 9 and the liquid outlet of the organic liquid container 15 are respectively connected to the liquid inlet of the second solid-phase extraction column 14 via pipelines, and the product collector 5 and the waste liquid bottle 16 are respectively connected to the liquid outlet of the second solid-phase extraction column 14 via pipelines. A three-way valve 22 is installed on each pipeline, and a solenoid valve 23 is connected to the three-way valve 22. A sterile filter membrane 20 is installed on the pipeline connecting the liquid inlet of the product collector 5 and the liquid outlet of the second solid-phase extraction column 14, and a ventilation filter membrane 21 is installed at the air inlet of the product collector 5. Among them, the first solid-phase extraction column 13 and the second solid-phase extraction column 14 are both C18 solid-phase extraction columns.

[0040] The AllinOne module may further include: an acetonitrile container 17, a sterile water reagent bag 18, a mixed solution syringe 19, a first ascorbic acid container 10, and a second ascorbic acid container 11; the acetonitrile container 17 is connected to the K2.2.2 / K2CO3 container 1 via a pipeline; the sterile water reagent bag 18 is connected to the K2.2.2 / K2CO3 container 1, the QMA solid-phase extraction cartridge 12, the first solid-phase extraction cartridge 13, and the second solid-phase extraction cartridge 14 via pipelines; the mixed solution syringe 19 is connected to the reaction container 4 via a pipeline. The first ascorbic acid container 10 is connected to the reaction container 4 via a pipeline; and the second ascorbic acid container 11 is connected to the product collector 5.

[0041] Example 2

[0042] The embodiment of the present invention provides a [ 18 F] Preparation method of K10-008, the preparation process is carried out on the AllinOne module of Example 1, and the preparation path is as follows:

[0043]

[0044] The specific steps of the preparation method include:

[0045] 1) Synthesis 18 F] Precursor compound of K10-008

[0046] The specific synthesis method can be referred to the literature: J Med Chem. 2011;54(23):8085-98 [ 18F] Synthesis steps of the precursor compound of K10-008.

[0047] 2) Place 22 mg of K2.2.2 (4,7,13,16,21,24-hexaoxo-1,10-diazabicyclo[8.8.8]hexacosane) and 1.6 mg of potassium carbonate into a K2.2.2 / K2CO3 container 1. Add 0.84 g of anhydrous acetonitrile and 0.16 mL of water into the K2.2.2 / K2CO3 container 1 via an acetonitrile container 17 and a sterile water reagent bag 18, respectively, to form a K2.2.2 / K2CO3 mixed solution, and disperse the solution evenly using an ultrasonic device.

[0048] 3) QMA solid phase extraction cartridge 12 was pre-treated with 10ml NaHCO3 solution and 10ml water. 18 F - Ions are transferred to the 18 F ion is injected into the ion injector 2 and then injected into the QMA column for adsorption. 18 F - ions, using the K2.2.2 / K2CO3 mixed solution in K2.2.2 / K2CO3 container 1 to elute the QMA column, containing 18 F - The ion eluate flows into the reaction vessel 4, and a nitrogen flow at 110°C and acetonitrile are introduced into the reaction vessel 4 to azeotropically dry and remove water twice;

[0049] 4) 2 mg of the precursor compound and 1 mL of dimethyl sulfoxide (anhydrous grade, 99.9% purity) were mixed in precursor compound container 3 and introduced into reaction container 4. The temperature in reaction container 4 was adjusted to 120°C using a heating element. After reacting for 10 minutes, the temperature was adjusted to room temperature and cooled for 5 minutes.

[0050] 5) 1 mL of hydrochloric acid (concentration of 4 mg / L) was added to the reaction vessel 4 via the acid container 6, and the temperature in the reaction vessel 4 was adjusted to 80° C. After a 7-minute deprotection reaction, the temperature was adjusted to freezing point. After cooling in an ice bath, sodium hydroxide solution was added to the reaction vessel 4 via an alkaline solution to neutralize and terminate the hydrolysis reaction; 8 mL of ascorbic acid solution was added to the reaction mixture in the reaction vessel 4 via the first ascorbic acid container 10 to dilute the reaction mixture. The diluted reaction mixture was drawn into the mixed solution injector 19 and then injected into the reaction vessel 4. This process was repeated at least twice to ensure that the reaction mixture was evenly mixed.

[0051] 6) The reaction mixture was extracted through a C18 solid phase extraction column to intercept the radioactive 18The F ion reactant is rinsed with sterile water in a sterile water reagent bag 18 on a C18 solid phase extraction column, and the waste liquid is introduced into a waste liquid bottle 16, and then the C18 solid phase extraction column is eluted with ethanol in an organic liquid container 15 to obtain a crude product;

[0052] 7) The crude product was passed into HPLC purification device 8 for separation and purification to obtain 18 F - HPLC mobile phase of ionic compounds; the HPLC mobile phase is extracted through a C18 solid phase extraction column to intercept 18 F - Ionic compounds are eluted with ethanol in the organic liquid container 15. The eluate is injected into the second ascorbic acid container 11 for mixing. The eluate is collected into the product collector 5 after passing through the sterile filter membrane 20 to obtain the final product [ 18 F]K10-008.

[0053] The total preparation time was 48 min, the radiochemical yield was 6.73±1.78%, and the purity was >98%.

[0054] Figure 2 yes[ 18 F] Radioactive high performance liquid chromatography (HPLC) profile of K10-008; Figure 3 yes[ 18 F]K10-008 and unlabeled compound [ 19 F] Ultraviolet HPLC (UV) chromatogram of K10-008 co-injection, the peak with retention time of 10.82 minutes (radioactive channel) corresponds to [ 18 F]K10-008, the peak at retention time 10.14 min (UV channel) corresponds to [ 19 F]K10-008.

[0055] Example 3

[0056] [ 18 F] The preparation method of K10-008 is the same as that of Example 2, except that the mass volume ratio of the precursor compound to dimethyl sulfoxide is 1 mg / mL.

[0057] Example 4

[0058] [ 18 F] The preparation method of K10-008 is the same as that of Example 2, except that the mass volume ratio of the precursor compound to dimethyl sulfoxide is 5 mg / mL.

[0059] Example 5

[0060] [ 18The preparation method of F]K10-008 is the same as that of Example 2, except that: in step 4), the temperature in the reaction vessel 4 is adjusted to 110°C by the heating element, and the reaction time is 15 minutes; in step 5), the temperature in the reaction vessel 4 is adjusted to 90°C, and the reaction time is 10 minutes.

[0061] Example 6

[0062] [ 18 The preparation method of F]K10-008 is the same as that of Example 2, except that: in step 4), the temperature in the reaction vessel 4 is adjusted to 130°C by the heating element, and the reaction time is 10 minutes; in step 5), the temperature in the reaction vessel 4 is adjusted to 100°C, and the reaction time is 7 minutes.

[0063] Example 7

[0064] [ 18 F] The preparation method of K10-008 is the same as that of Example 2, except that in step 3), 2 mg of the precursor compound is mixed with 1 mL of acetonitrile.

[0065] Example 8

[0066] [ 18 F] The preparation method of K10-008 is the same as that of Example 2, except that in step 3), 2 mg of the precursor compound is mixed with 1 mL of N,N-dimethylformamide.

[0067] Example 9

[0068] [ 18 F] The preparation method of K10-008 is the same as that of Example 2, except that: in step 5), 1 mL of sulfuric acid is added to the reaction container 4 through the acid container 6.

[0069] Example 10

[0070] [ 18 F] The preparation method of K10-008 is the same as that of Example 2, except that: in step 5), 1 mL of phosphoric acid is added to the reaction container 4 through the acid container 6.

[0071] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any modifications or substitutions that can be easily conceived by a person skilled in the art within the technical scope disclosed in the present invention should be included in the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be based on the scope of protection of the claims.

Claims

1. A 18 F] A method for preparing K10-008, characterized in that: include: 1) Synthesis 18 F] precursor compound of K10-008; 2) will contain 18 F - A mixed solution of K2.2.2 ions and potassium carbonate and a precursor compound dissolved in a fluorinated solvent are placed in a reaction vessel for a first heating reaction to obtain a reaction solution, and an acidic substance is added to the reaction solution for a second heating reaction to synthesize [ 18 F]K10-008; 3) The synthesized [ 18 F]K10-008 is purified by solid phase extraction column to obtain the finished product.

2. The preparation method according to claim 1, characterized in that The temperature of the first heating reaction is 110-130° C., and the reaction time is 10-15 min; the temperature of the second heating reaction is 80-100° C., and the reaction time is 7-10 min.

3. The preparation method according to claim 1, characterized in that The fluorinated solvent includes one or more of dimethyl sulfoxide, acetonitrile or N,N-dimethylformamide; the acidic substance includes one or more of hydrochloric acid, sulfuric acid or phosphoric acid.

4. The preparation method according to claim 1, characterized in that In the step 2), before the reaction, the radioactive 18 F - The ions were adsorbed by QMA solid phase extraction column and eluted with a mixed solution of K2.2.2 and potassium carbonate to obtain 18 F - A mixed solution of ionic K2.2.2 and potassium carbonate.

5. The preparation method according to claim 1, characterized in that In the step 3), the synthesized [ 18 After the step of purifying K10-008 by solid phase extraction column, the step further includes: separating and purifying the purified crude product by HPLC; 18 F - ions, and eluted with an organic solvent; wherein, before HPLC separation and purification, ascorbic acid is added to the crude product; after HPLC separation and purification, ascorbic acid is added to the HPLC mobile phase.

6. The preparation method according to claim 1, characterized in that The preparation process is carried out on the AllinOne module; the AllinOne module includes: a K2.2.2 / K2CO3 container connected in sequence through pipelines, 18 F - An ion injector, a precursor compound container, a reaction container and a product collector; the AllinOne module also includes: an acid container, an alkaline container and a first solid-phase extraction column; the acid container and the alkaline container are respectively connected to the reaction container through pipelines; the first solid-phase extraction column is respectively connected to the reaction container and the product collector through pipelines; the reaction container is provided with a heating element.

7. The preparation method according to claim 6, characterized in that The AllinOne module also includes: a QMA solid phase extraction cartridge, a second solid phase extraction cartridge, an HPLC purification device, an HPLC mobile phase container, an organic liquid container, and a waste liquid bottle; described 18 F - The ion injector and the K2.2.2 / K2CO3 container are respectively connected to the liquid inlet of the QMA solid phase extraction column through pipelines; the liquid inlet of the reaction container and the liquid inlet of the waste liquid bottle are respectively connected to the liquid outlet of the QMA solid phase extraction column through pipelines; The liquid outlet of the reaction container and the liquid outlet of the organic liquid container are respectively connected to the liquid inlet of the first solid phase extraction column through pipelines, and the liquid inlet of the HPLC purification device and the liquid inlet of the waste liquid bottle are respectively connected to the liquid outlet of the first solid phase extraction column through pipelines; The liquid outlet of the HPLC mobile phase container and the liquid outlet of the organic liquid container are respectively connected to the liquid inlet of the second solid phase extraction column through pipelines, and the product collector and the waste liquid bottle are respectively connected to the liquid outlet of the second solid phase extraction column through pipelines.

8. The preparation method according to claim 7, characterized in that A three-way valve is provided on each of the pipelines, and the three-way valve is connected to the electromagnetic valve; a sterile filter membrane is provided on the pipeline connecting the liquid inlet of the product collector and the liquid outlet of the second solid phase extraction column.

9. The preparation method according to claim 8, characterized in that The preparation method comprises: Radioactive substances produced by accelerators 18 F - Ions are transferred through the shielding gas 18 F - The solution was injected into the ion injector and then injected into the QMA solid phase extraction cartridge. The solution was eluted with a mixed solution of K2.2.2 and potassium carbonate in the K2.2.2 / K2CO3 container. The eluate entered the reaction vessel. Acetonitrile was added to the reaction vessel to azeotropically remove water. The precursor compound and the fluorinated solvent are mixed in a precursor compound container and introduced into a reaction container; the temperature in the reaction container is adjusted to 110°C to 130°C by a heating element, and the reaction is carried out for 10 minutes to 15 minutes; An acidic substance is added to the reaction vessel through an acid solution container, and the temperature in the reaction vessel is adjusted to 80° C. to 100° C. After a deprotection reaction is carried out for 7 min to 10 min, the temperature is adjusted to freezing point, and after cooling in an ice bath, an alkaline substance is added to the reaction vessel through an alkaline solution container to neutralize and terminate the hydrolysis reaction, thereby obtaining a reaction mixture; The reaction mixture is extracted through a first solid phase extraction column to intercept radioactive 18 F - The ionic reactant is extracted by eluting the first solid phase extraction column with an organic solvent in an organic liquid container to obtain a crude product; The crude product was passed into HPLC purification device for separation and purification to obtain 18 F - HPLC mobile phase of ionic compounds; extracting the HPLC mobile phase through a second solid phase extraction column to intercept 18 The compound of F ion is eluted with an organic solvent to remove the second solid phase extractant, and the eluate is collected into a product collector after passing through a sterile filter membrane to obtain the final product [ 18 F]K10-008.

10. A 18 F]K10-008, characterized in that The preparation method according to any one of claims 1 to 9 is used to prepare the compound.

Images